These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9076373)

  • 1. Pragmatic and mechanistic trials.
    Califf RM; Woodlief LH
    Eur Heart J; 1997 Mar; 18(3):367-70. PubMed ID: 9076373
    [No Abstract]   [Full Text] [Related]  

  • 2. [The long way of angiotensin-converting enzyme inhibitors in the fight against cardiovascular diseases].
    Ferrari R; Ambrosio G; Chiariello M
    Ital Heart J; 2005 Nov; 6 Suppl 7():3S-4S. PubMed ID: 16485511
    [No Abstract]   [Full Text] [Related]  

  • 3. Telmisartan in high-risk patients intolerant of ACE inhibitors.
    Thompson M; Heneghan C; Perera R
    Lancet; 2009 Feb; 373(9662):457-8; author reply 459. PubMed ID: 19200908
    [No Abstract]   [Full Text] [Related]  

  • 4. The Heart Outcomes Protection Evaluation (HOPE) study: relevance to ophthalmological practice?
    Barnett AH
    Eye (Lond); 2000 Feb; 14 ( Pt 1)():1-2. PubMed ID: 10755090
    [No Abstract]   [Full Text] [Related]  

  • 5. [The ONTARGET trial].
    Verdecchia P; Terrosu P
    G Ital Cardiol (Rome); 2009 Feb; 10(2):67-72. PubMed ID: 19348142
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials.
    Shunan F; Jiqing Y; Xue D
    J Renin Angiotensin Aldosterone Syst; 2018; 19(4):1470320318803495. PubMed ID: 30296880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.
    Tocci G; Paneni F; Palano F; Sciarretta S; Ferrucci A; Kurtz T; Mancia G; Volpe M
    Am J Hypertens; 2011 May; 24(5):582-90. PubMed ID: 21331058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arresting cardiovascular disease progression. Early treatment may counteract high risk.
    Ram CV; Vergne-Marini P
    Postgrad Med; 2004 Aug; 116(2):45-8. PubMed ID: 15323153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experiences with the realisation of innovative study designs using the example of the HOPE-study].
    Rangoonwala B
    Dtsch Med Wochenschr; 2005 Jul; 130 Suppl 2():S82-5. PubMed ID: 15988674
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical trials of renin-angiotensin antagonists in Japan].
    Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):182-3. PubMed ID: 18421845
    [No Abstract]   [Full Text] [Related]  

  • 11. Access to advances in cardiology.
    Lye M
    Lancet; 1997 Oct; 350(9085):1162-3. PubMed ID: 9343518
    [No Abstract]   [Full Text] [Related]  

  • 12. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
    Xie X; Liu Y; Perkovic V; Li X; Ninomiya T; Hou W; Zhao N; Liu L; Lv J; Zhang H; Wang H
    Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research.
    Ferrario CM
    J Renin Angiotensin Aldosterone Syst; 2006 Mar; 7(1):3-14. PubMed ID: 17083068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-angiotensin system modulating treatments in the management of cardiovascular disease.
    Rydén L
    Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i1. PubMed ID: 10956308
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema.
    Beavers CJ; Dunn SP; Macaulay TE
    Ann Pharmacother; 2011 Apr; 45(4):520-4. PubMed ID: 21427294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-receptor blockers in prevention of cardiovascular events: are they as effective as angiotensin-converting enzyme inhibitors?
    Teo KK
    Pol Arch Med Wewn; 2009; 119(1-2):8-10. PubMed ID: 19341172
    [No Abstract]   [Full Text] [Related]  

  • 18. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice.
    Pitt B
    Heart; 2009 Aug; 95(15):1205-8. PubMed ID: 19401281
    [No Abstract]   [Full Text] [Related]  

  • 19. The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial.
    Pfeffer MA; Domanski M; Verter J; Dunlap M; Flaker GC; Gersh B; Hsia J; Goldberg AD; Limacher MC; Maggioni AP; Rosenberg Y; Rouleau JL; Warnica JW; Wasserman AG; Braunwald E;
    Am Heart J; 2001 Sep; 142(3):375-7. PubMed ID: 11526345
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
    BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.